ProMIS Biotech Hopes to Prove Amyloid Theory in Alzheimer’s with New Targeted Therapies

ProMIS Biotech Hopes to Prove Amyloid Theory in Alzheimer’s with New Targeted Therapies
In the wake of the failure of the investigational drug solanezumab, which stirred the debate over whether the prevailing amyloid theory of Alzheimer’s disease is still a viable working hypothesis, ProMIS Neurosciences announced their contribution to Alzheimer’s amyloid-related drug development. The announcement was accompanied by a commentary interpreting the failure of certain drugs — and offering an explanation

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *